Bcl-2 associated with severity of manic symptoms in bipolar patients in a manic phase

Chen, Wei‐Ting; Huang, Tiao‐Lai; Tsai, Meng-Chang

doi:10.1016/j.psychres.2014.12.020

Cited by 11 publications

(3 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, indicators related to cell apoptosis such as S100B and Bcl-2 were related to the acute phase of schizophrenia [ 24 ] and bipolar I mania. [ 25 , 26 ] No studies have been done into the relationship of serum levels of biomarkers related to oxidative stress and cell apoptosis, or the relationship between brain tissue damage and biomarkers related to oxidative stress, in AUD patients.…”

Section: Introductionmentioning

confidence: 99%

Brain-derived neurotrophic factor and glutathione peroxidase as state biomarkers in alcohol use disorder patients undergoing detoxification

Chen

Huang

et al. 2020

Medicine

Self Cite

View full text Add to dashboard Cite

The pathophysiology of alcohol use disorder (AUD) is not totally clear. The aim of this study was to investigate the serum levels of brain-derived neurotrophic factor (BDNF) and oxidative stress markers in AUD patients during alcohol detoxification. Evaluation of changes in BDNF, glutathione peroxidase (GPX), catalase, superoxide dismutase, thiobarbituric acid reactive substances, 8-hydroxy 2’-deoxyguanosine, PCC and S100B were carried out. 14 AUD inpatients and 20 healthy control subjects were recruited for this study. The serum BDNF, S100B and oxidative stress markers were measured with assay kits. Serum levels of catalase, GPX, PCC and 8-hydroxy 2’-deoxyguanosine were significantly higher in the AUD group subjects than in the controls ( P < .05). However, BDNF levels were lower in the AUD group than in the controls ( P < .05). After alcohol detoxification treatment, the GPX levels in the AUD group dropped ( P < .05) and the BDNF levels rose ( P < .05). The results suggest that serum BDNF and GPX levels might be state biomarkers for AUD patients undergoing alcohol detoxification.

show abstract

Section: Introductionmentioning

confidence: 99%

Brain-derived neurotrophic factor and glutathione peroxidase as state biomarkers in alcohol use disorder patients undergoing detoxification

Chen

Huang

et al. 2020

Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Overlapping activity on different pathways is characteristic of Li; however, epigenetic contributions on neurotrophins, apoptosis pathways, and glycogen synthase kinase-3 (GSK-3b) stand out, among the included papers, as central targets of lithium (D'Addario et al, 2012;Kao et al, 2013;Dell'Osso et al, 2014;Dwivedi and Zhang, 2015). Several studies have identified a negative correlation between Bcl-2 levels and positive symptoms in SCZ and manic symptoms in BD (Tsai et al, 2013;Chen et al, 2015), implying a dysregulation of apoptotic pathways in these disorders. Findings from our search reflect that Li can reverse not only the decreased levels of Bcl-2 and Bcl-XL but also inhibit the expression of proapoptotic molecules such as BAD, BAX and caspase-3 (Dwivedi and Zhang, 2015), highlighting the anti-apoptotic properties of this mood stabilizer.…”

Section: Summary Of Main Findingsmentioning

confidence: 99%

Dissecting the Epigenetic Changes Induced by Non-Antipsychotic Mood Stabilizers on Schizophrenia and Affective Disorders: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

Background: Epimutations secondary to gene-environment interactions have a key role in the pathophysiology of major psychiatric disorders. In vivo and in vitro evidence suggest that mood stabilizers can potentially reverse epigenetic deregulations found in patients with schizophrenia or mood disorders through mechanisms that are not yet fully understood. However, their activity on epigenetic processes has made them a research target for therapeutic approaches. Methods:We conducted a comprehensive literature search of PubMed and EMBASE for studies investigating the specific epigenetic changes induced by non-antipsychotic mood stabilizers (valproate, lithium, lamotrigine, and carbamazepine) in animal models, human cell lines, or patients with schizophrenia, bipolar disorder, or major depressive disorder. Each paper was reviewed for the nature of research, the species and tissue examined, sample size, mood stabilizer, targeted gene, epigenetic changes found, and associated psychiatric disorder. Every article was appraised for quality using a modified published process and those who met a quality score of moderate or high were included.Results: A total of 2,429 records were identified; 1,956 records remained after duplicates were removed and were screened via title, abstract and keywords; 129 records were selected for full-text screening and a remaining of 38 articles were included in the qualitative synthesis. Valproate and lithium were found to induce broader epigenetic changes through different mechanisms, mainly DNA demethylation and histones acetylation. There was less literature and hence smaller effects attributable to lamotrigine and carbamazepine could be associated overall with the small number of studies on these agents. Findings were congruent across sample types.Conclusions: An advanced understanding of the specific epigenetic changes induced by classic mood stabilizers in patients with major psychiatric disorders will facilitate Frontiers in Pharmacology | www.frontiersin.org

show abstract

“…Therefore, we stratified our patients according to the Bcl-2 rs956572 genotype as Bcl-2 G carriers ( n = 76) and A homozygotes ( n = 28), matched for confounding factors including sex, age, education level, apolipoprotein E4 status, duration of disease, and Mini Mental State Examination (MMSE) score. Because the Bcl-2 genotypes have been reported to influence psychiatric presentation in bipolar disorders [ 5 , 6 , 20 , 21 ], we also included Neuropsychiatric Inventory (NPI) scores to evaluate whether the genotype groups affected the behavioral presentations.…”

Section: Introductionmentioning

confidence: 99%

Associations of Bcl-2 rs956572 genotype groups in the structural covariance network in early-stage Alzheimer’s disease

Chang

Huang

et al. 2018

Alz Res Therapy

View full text Add to dashboard Cite

BackgroundAlzheimer’s disease (AD) is a complex neurodegenerative disease, and genetic differences may mediate neuronal degeneration. In humans, a single-nucleotide polymorphism in the B-cell chronic lymphocytic leukemia/lymphoma-2 (Bcl-2) gene, rs956572, has been found to significantly modulate Bcl-2 protein expression in the brain. The Bcl-2 AA genotype has been associated with reduced Bcl-2 levels and lower gray matter volume in healthy populations. We hypothesized that different Bcl-2 genotype groups may modulate large-scale brain networks that determine neurobehavioral test scores.MethodsGray matter structural covariance networks (SCNs) were constructed in 104 patients with AD using T1-weighted magnetic resonance imaging with seed-based correlation analysis. The patients were stratified into two genotype groups on the basis of Bcl-2 expression (G carriers, n = 76; A homozygotes, n = 28). Four SCNs characteristic of AD were constructed from seeds in the default mode network, salience network, and executive control network, and cognitive test scores served as the major outcome factor.ResultsFor the G carriers, influences of the SCNs were observed mostly in the default mode network, of which the peak clusters anchored by the posterior cingulate cortex seed determined the cognitive test scores. In contrast, genetic influences in the A homozygotes were found mainly in the executive control network, and both the dorsolateral prefrontal cortex seed and the interconnected peak clusters were correlated with the clinical scores. Despite a small number of cases, the A homozygotes showed greater covariance strength than the G carriers among all four SCNs.ConclusionsOur results suggest that the Bcl-2 rs956572 polymorphism is associated with different strengths of structural covariance in AD that determine clinical outcomes. The greater covariance strength in the four SCNs shown in the A homozygotes suggests that different Bcl-2 polymorphisms play different modulatory roles.Electronic supplementary materialThe online version of this article (10.1186/s13195-018-0344-4) contains supplementary material, which is available to authorized users.

show abstract

Bcl-2 associated with severity of manic symptoms in bipolar patients in a manic phase

Cited by 11 publications

References 45 publications

Brain-derived neurotrophic factor and glutathione peroxidase as state biomarkers in alcohol use disorder patients undergoing detoxification

Brain-derived neurotrophic factor and glutathione peroxidase as state biomarkers in alcohol use disorder patients undergoing detoxification

Dissecting the Epigenetic Changes Induced by Non-Antipsychotic Mood Stabilizers on Schizophrenia and Affective Disorders: A Systematic Review

Associations of Bcl-2 rs956572 genotype groups in the structural covariance network in early-stage Alzheimer’s disease

Contact Info

Product

Resources

About